中国肺癌杂志2025，Vol.28Issue(2)：81-94,14.DOI:10.3779/j.issn.1009-3419.2025.102.01
MET异常NSCLC诊疗专家共识(2025版)
Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities(2025 Version)
摘要
Abstract
The mesenchymal-epithelial transition factor(MET)gene,located on human chromosome 7,plays a crucial role in the regulation of physiological processes such as cell proliferation,migration,invasion,and angiogenesis.The MET gene is one of the key drivers in non-small cell lung cancer(NSCLC),with various forms of abnormalities in-cluding MET exon 14(METex14)skipping mutations,MET gene amplification,MET fusions,MET protein overexpres-sion,MET activating mutations and etc.With an increasing understanding of the mechanisms underlying MET abnor-malities,therapeutic strategies targeting these abnormalities have gained significant attention,and numerous studies have confirmed that NSCLC patients with MET abnormalities can derive substantial benefits from such treatments.Lung Can-cer Specialty Committee of Chinese Elderly Health Care Association organized a panel of experts to provide professional recommendations on current clinical issues in the diagnosis and treatment of MET-aberrant NSCLC,combining clinical practice experiences and evidence-based medical evidences.The"Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities(2025 Version)"has been formulated to provide standardized guidances for clinical practice in China,with the aim of optimizing the treatment outcomes.关键词
肺肿瘤/MET异常/MET抑制剂/治疗Key words
Lung neoplasms/MET abnormalities/MET inhibitors/Treatment引用本文复制引用
陈军,韩宝惠,胡毅,胡坚,中国老年保健协会肺癌专业委员会..MET异常NSCLC诊疗专家共识(2025版)[J].中国肺癌杂志,2025,28(2):81-94,14.基金项目
This paper was supported by the grants from Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-061B)and Tianjin Health Science and Technology Project Key Disciplines(No.TJWJ2022XK005)(Both to Jun CHEN). 本文受天津市医学重点建设学科(No.TJYXZDXK-061B)和天津卫生健康科技项目重点学科专项(No.TJWJ2022XK005)资助 （Specialty）
